Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced significant advancements in its Radio DARPin Therapy (RDT) platform, showcasing new preclinical data that highlights the technology's potential for targeted radionuclide delivery. The findings, which will be presented at the American Association for Cancer Research Annual Meeting on April 18, 2023, demonstrate reduced kidney accumulation and high tumor penetration of DARPins due to specific engineering. This innovative approach addresses historical safety concerns associated with small protein-based delivery vectors. The company aims to expand the use of RDT to a broader range of tumor targets, leveraging collaborations with major pharmaceutical firms such as Novartis.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) held its Annual General Meeting where shareholders approved all Board of Directors' motions. Key approvals included the financial statements for 2022 and the carry-forward of earnings totaling CHF 124 million, reducing prior losses from CHF 216 million to CHF 92 million. The Board received discharge for 2022, and all members were re-elected for another year. KPMG AG Zurich was confirmed as statutory auditors for 2023. The meeting also endorsed compensation motions for the Board and Management.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced its Annual General Meeting scheduled for April 4, 2023, at 14:00 CET in Schlieren, Switzerland. The meeting will provide insights into the company's developments and future directions. Key financial dates include the Interim Management Statement for Q1 2023 on May 11 and the Half-year results on August 24. The company focuses on developing DARPin therapeutics, custom-built proteins aimed at addressing unmet medical needs, particularly in oncology and infectious diseases, with partnerships established with major pharmaceutical firms.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) reported significant advancements in its 2022 corporate highlights and financial results. The company initiated a Phase 1 study for MP0533, a tri-specific T-cell engager targeting acute myeloid leukemia, and presented promising preclinical data at the ASH Annual Meeting. Financially, Molecular Partners achieved CHF 189.6 million in total revenues, a substantial increase from CHF 9.8 million in 2021, resulting in a net profit of CHF 117.8 million. The company maintains a strong cash position of CHF 249.1 million, expected to fund operations into 2026. 2023 guidance indicates operating expenses of CHF 70-80 million.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm specializing in DARPin therapeutics, will release its 2022 financial results on March 9, 2023, followed by an investor call on March 10, 2023. The call will summarize key highlights from Q4 and the full year. CEO Patrick Amstutz is scheduled to present at the 43rd Annual Cowen Health Care Conference on March 8, 2023, in Boston, MA. Investors can access a live webcast of the results presentation on the company’s website, with a replay available for 90 days thereafter.